BSG
Basigin
As of the edition of 20 October 2026, BSG (basigin, UniProt P35613) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35613
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 18
- Disease areas
- Immune system
- Registered trials of its drugs
- 2
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| DS-1471a | Stopped | Phase 1 | none listed |
| Gavilimomab | Went quiet | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Daiichi Sankyo | Route A |
| Abgenix | Route A |
The other 0 companies at BSG
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at BSG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.